A high-throughput screening assay for fungicidal compounds against cryptococcus neoformans

Journal of Biomolecular Screening

Volumn 19, Issue 2, 2014, Pages 270-277

  Rabjohns, Jennifer L A ^a   Park, Yoon Dong ^a   Dehdashti, Jean ^b   Sun, Wei ^b   Henderson, Christina ^a   Zelazny, Adrian ^a   Metallo, Steven J ^c   Zheng, Wei ^b   Williamson, Peter R ^a,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

alamarBlue assay; Cryptococcus neoformans; fungicidal screen; high throughput screen

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; AZOXYSTROBIN; CAPTAN; FUNGICIDE; ITRACONAZOLE; KETOCONAZOLE; LANOCONAZOLE; LULICONAZOLE; POSACONAZOLE; PYRITHIONE ZINC; PYRROLNITRIN; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

ARTICLE; ASSAY; CELL DENSITY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; HIGH THROUGHPUT SCREENING; IC 50; NONHUMAN; PRIORITY JOURNAL;

ALAMARBLUE ASSAY; CRYPTOCOCCUS NEOFORMANS; FUNGICIDAL SCREEN; HIGH-THROUGHPUT SCREEN;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MENINGITIS, CRYPTOCOCCAL; SMALL MOLECULE LIBRARIES; THIAZOLES;

EID: 84892686577     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113496847     Document Type: Article

References (30)

1. Park B. J., Wannemuehler K. A., Marston B. J., et al. Estimation of the Current Global Burden of Cryptococcal Meningitis among Persons Living with HIV/AIDS. AIDS. 2009 ; 23: 525-530
2. Pyrgos V., Seitz A., Steiner C., et al. Epidemiology of Cryptococcal Meningitis in the US: 1997-2009. PloS One. 2013 ; 8: e56269
3. Jarvis J. N., Harrison T. S. HIV-Associated Cryptococcal Meningitis. AIDS. 2007 ; 21: 2119-2129 (Pubitemid 350287209)
4. Bii C. C., Makimura K., Abe S., et al. Antifungal Drug Susceptibility of Cryptococcus neoformans from Clinical Sources in Nairobi, Kenya. Mycoses. 2007 ; 50: 25-30 (Pubitemid 46046416)
5. Pfaller M. A., Castanheira M., Diekema D. J., et al. Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole, Posaconazole, and Voriconazole When Testing Cryptococcus neoformans as Determined by the CLSI Broth Microdilution Method. Diagn. Microbiol. Infect. Dis. 2011 ; 71: 252-259
6. Lewis J. S., Graybill J. R. Fungicidal versus Fungistatic: What's in a Word?. Expert Opin. Pharmacother. 2008 ; 9: 927-935 (Pubitemid 351593740)
7. Saag M. S., Powderly W. G., Cloud G. A., et al. Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal Meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N. Engl. J. Med. 1992 ; 326: 83-89
8. Bicanic T., Meintjes G., Wood R., et al. Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole. Clin. Infect. Dis. 2007 ; 45: 76-80 (Pubitemid 46984619)
9. Bicanic T., Muzoora C., Brouwer A. E., et al. Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. Clin. Infect. Dis. 2009 ; 49: 702-709
10. de Almeida S. M., Boritza K., Cogo L. L., et al. Quantification of Cerebrospinal Fluid Lactic Acid in the Differential Diagnosis between HIV Chronic Meningitis and Opportunistic Meningitis. Clin. Chem. Lab. Med. 2011 ; 49: 891-896
11. Diamond R. D., Bennett J. E. Prognostic Factors in Cryptococcal Meningitis: A Study in 111 Cases. Ann. Intern. Med. 1974 ; 80: 176-181
12. Price M. S., Betancourt-Quiroz M., Price J. L., et al. Cryptococcus neoformans Requires a Functional Glycolytic Pathway for Disease but Not Persistence in the Host. MBio. 2011 ; 2: e00103 - e001011
13. Hu G., Hacham M., Waterman S. R., et al. PI3K Signaling of Autophagy Is Required for Starvation Tolerance and Virulence of Cryptococcus neoformans. J. Clin. Invest. 2008 ; 118: 1186-1197 (Pubitemid 351364625)
14. Waterman S., Hacham M., Hu G., et al. Role of a CUF1-CTR4 Copper Regulatory Axis in the Virulence of Cryptococcus neoformans. J. Clin. Invest. 2007 ; 117: 794-802 (Pubitemid 46348538)
15. Waterman S. R., Park Y. D., Raja M., et al. Role of CTR4 in the Virulence of Cryptococcus neoformans. MBio. 2012 ; 3: e00285-12
16. Kmetzsch L., Staats C. C., Simon E., et al. The GATA-Type Transcriptional Activator Gat1 Regulates Nitrogen Uptake and Metabolism in the Human Pathogen Cryptococcus neoformans. Fungal Genet. Biol. 2011 ; 48: 192-199
17. Williamson P. R. Biochemical and Molecular Characterization of the Diphenol Oxidase of Cryptococcus neoformans: Identification as a Laccase. J. Bacteriol. 1994 ; 176: 656-664 (Pubitemid 24043954)
18. Doering T. L. How Sweet It Is! Cell Wall Biogenesis and Polysaccharide Capsule Formation. Cryptococcus neoformans. Annu. Rev. Microbiol. 2009 ; 63: 223-247
19. Ikeda R., Sugita T., Jacobson E. S., et al. Effects of Melanin upon Susceptibility of Cryptococcus to Antifungals. Microbiol. Immunol. 2003 ; 47: 271-277 (Pubitemid 36460563)
20. Espinel-Ingroff A., Canton E., Peman J., et al. Comparison of 24-Hour and 48-Hour Voriconazole MICs as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) in Three Laboratories: Results Obtained with 2,162 Clinical Isolates of Candida spp. and Other Yeasts. J. Clin. Microbiol. 2009 ; 47: 2766-2771
21. Guo J., Parise R. A., Joseph E., et al. Efficacy, Pharmacokinetics, Tissue Distribution, and Metabolism of the Myc-Max Disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in Mice. Cancer Chemother. Pharmacol. 2009 ; 63: 615-625
22. Maxwell M. J., Messer S. A., Hollis R. J., et al. Evaluation of Etest Method for Determining Voriconazole and Amphotericin B MICs for 162 Clinical Isolates of Cryptococcus neoformans. J. Clin. Microbiol. 2003 ; 41: 97-99 (Pubitemid 36098560)
23. Hamid R., Rotshteyn Y., Rabadi L., et al. Comparison of Alamar Blue and MTT Assays for High Through-put Screening. Toxicol. In Vitro. 2004 ; 18: 703-710 (Pubitemid 38900879)
24. Himmelreich U., Dzendrowskyj T. E., Allen C., et al. Cryptococcomas Distinguished from Gliomas with MR Spectroscopy: An Experimental Rat and Cell Culture Study. Radiology. 2001 ; 220: 122-128 (Pubitemid 32577971)
25. Fan W., Kraus P. R., Boily M. J., et al. Cryptococcus neoformans Gene Expression during Murine Macrophage Infection. Eukaryot. Cell. 2005 ; 4: 1420-1433 (Pubitemid 41176696)
26. Jacobson E. S., Goodner A. P., Nyhus K. J. Ferrous Iron Uptake in Cryptococcus neoformans. Infect. Immun. 1998 ; 66: 4169-4175 (Pubitemid 28402688)
27. Gomez-Curet I., Perkins R. S., Bennett R., et al. c-Myc Inhibition Negatively Impacts Lymphoma Growth. J. Pediatr. Surg. 2006 ; 41: 207-211 (Pubitemid 43067518)
28. Bandukwala H. S., Gagnon J., Togher S., et al. Selective Inhibition of CD4+ T-cell Cytokine Production and Autoimmunity by BET Protein and c-Myc Inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2012 ; 109: 14532-14537
29. Whitehead K., Karr N., Mitragotri S. Discovery of Synergistic Permeation Enhancers for Oral Drug Delivery. J. Control Release. 2008 ; 128: 128-133
30. Huang M. J., Cheng Y. C., Liu C. R., et al. A Small-Molecule c-Myc Inhibitor, 10058-F4, Induces Cell-Cycle Arrest, Apoptosis, and Myeloid Differentiation of Human Acute Myeloid Leukemia. Exp. Hematol. 2006 ; 34: 1480-1489